{"id":"tap-144-sr-3m","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Injection site reaction"},{"rate":null,"effect":"Decreased libido"},{"rate":null,"effect":"Erectile dysfunction"},{"rate":null,"effect":"Bone density loss"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Leuprolide works by binding to GnRH receptors in the pituitary gland, initially causing a surge in LH and FSH (flare effect) followed by sustained suppression of these hormones. This leads to castration-level testosterone or estrogen reduction, making it effective for hormone-dependent cancers and certain endocrine disorders. The SR (sustained-release) 3-month formulation provides extended drug delivery over a quarterly dosing interval.","oneSentence":"TAP-144-SR is a sustained-release formulation of leuprolide, a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone to reduce sex hormone production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:52.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Precocious puberty"}]},"trialDetails":[{"nctId":"NCT01546649","phase":"PHASE3","title":"A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-04","conditions":"Premenopausal Breast Cancer","enrollment":167},{"nctId":"NCT01546623","phase":"PHASE3","title":"A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-03","conditions":"Prostate Cancer","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TAP-144-SR(3M)","genericName":"TAP-144-SR(3M)","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAP-144-SR(3M) is being studied in clinical trials for Prostate Cancer and Premenopausal Breast Cancer. The exact mechanism of TAP-144-SR(3M) is not specified in the provided facts, but it is being compared to TAP-144-SR(6M) in a Phase 3 study for Prostate Cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}